Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jun 09, 2023 7:14pm
134 Views
Post# 35489495

RE:RE:RE:RE:RE:RE:Conditions are right for biopharma M&A to break out

RE:RE:RE:RE:RE:RE:Conditions are right for biopharma M&A to break outRelated to Big Pharma ramping up M&A activity in the second half of 2023 . 

June 08, 2023 -  The Federal Trade Commission (FTC)  is building out its deep dive into the pharmacy benefit management industry yet again.


Group purchasing organization (GPOs) are also often sister companies to PBMs, which has similarly drawn ire from legislators.

Interest in reforms to the pharmacy benefit management market has grown alongside rising drug prices. Pharmaceutical companies have pointed the finger at PBMs as the culprit in price increases, and the lack of transparency in the industry lends credence to those claims to many policymakers.

https://www.fiercehealthcare.com/payers/ftc-adds-third-gpo-its-investigation-pharmacy-benefit-managers

<< Previous
Bullboard Posts
Next >>